Trial Profile
A retrospective study to evaluate different types and dosages of Botulinum Toxin-A in patients with neurogenic detrusor overactivity (NDO) secondary to spinal cord lesion (SCL)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2016
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Detrusor instability; Overactive bladder
- Focus Therapeutic Use
- 04 Nov 2016 New trial record
- 16 Sep 2016 Results presented at the 46th Annual Meeting of the International Continence Society